<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p60" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_60{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t2_60{left:341px;bottom:30px;}
#t3_60{left:348px;bottom:25px;letter-spacing:0.11px;}
#t4_60{left:377px;bottom:30px;}
#t5_60{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t6_60{left:540px;bottom:30px;}
#t7_60{left:546px;bottom:25px;letter-spacing:0.07px;}
#t8_60{left:44px;bottom:77px;letter-spacing:0.1px;word-spacing:-0.05px;}
#t9_60{left:44px;bottom:63px;letter-spacing:0.1px;}
#ta_60{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#tb_60{left:285px;bottom:827px;letter-spacing:-0.39px;word-spacing:0.12px;}
#tc_60{left:996px;bottom:873px;letter-spacing:-0.1px;}
#td_60{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#te_60{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#tf_60{left:1109px;bottom:28px;letter-spacing:0.29px;}
#tg_60{left:36px;bottom:778px;letter-spacing:0.47px;}
#th_60{left:36px;bottom:760px;letter-spacing:0.23px;}
#ti_60{left:329px;bottom:778px;letter-spacing:0.29px;word-spacing:-0.13px;}
#tj_60{left:738px;bottom:778px;letter-spacing:0.28px;word-spacing:-0.12px;}
#tk_60{left:1065px;bottom:778px;letter-spacing:0.34px;}
#tl_60{left:1065px;bottom:640px;letter-spacing:-0.1px;}
#tm_60{left:1065px;bottom:622px;letter-spacing:-0.09px;}
#tn_60{left:1065px;bottom:603px;letter-spacing:-0.08px;}
#to_60{left:1072px;bottom:543px;letter-spacing:-0.09px;}
#tp_60{left:1072px;bottom:524px;letter-spacing:-0.06px;}
#tq_60{left:1072px;bottom:506px;letter-spacing:-0.08px;}
#tr_60{left:1072px;bottom:488px;letter-spacing:-0.09px;}
#ts_60{left:1072px;bottom:469px;letter-spacing:-0.25px;}
#tt_60{left:667px;bottom:751px;letter-spacing:-0.13px;}
#tu_60{left:690px;bottom:758px;}
#tv_60{left:667px;bottom:734px;letter-spacing:-0.06px;}
#tw_60{left:667px;bottom:717px;letter-spacing:-0.11px;}
#tx_60{left:734px;bottom:725px;}
#ty_60{left:747px;bottom:717px;letter-spacing:-0.09px;}
#tz_60{left:667px;bottom:701px;letter-spacing:-0.1px;}
#t10_60{left:667px;bottom:684px;letter-spacing:-0.1px;}
#t11_60{left:909px;bottom:691px;letter-spacing:-0.11px;}
#t12_60{left:667px;bottom:667px;letter-spacing:-0.09px;}
#t13_60{left:667px;bottom:650px;letter-spacing:-0.09px;}
#t14_60{left:733px;bottom:658px;}
#t15_60{left:293px;bottom:706px;letter-spacing:-0.1px;}
#t16_60{left:374px;bottom:713px;letter-spacing:-0.1px;}
#t17_60{left:293px;bottom:687px;letter-spacing:-0.09px;}
#t18_60{left:293px;bottom:655px;letter-spacing:-0.1px;}
#t19_60{left:293px;bottom:622px;letter-spacing:-0.1px;}
#t1a_60{left:396px;bottom:629px;}
#t1b_60{left:36px;bottom:664px;letter-spacing:-0.1px;}
#t1c_60{left:667px;bottom:580px;letter-spacing:-0.13px;}
#t1d_60{left:690px;bottom:587px;}
#t1e_60{left:667px;bottom:563px;letter-spacing:-0.06px;}
#t1f_60{left:667px;bottom:546px;letter-spacing:-0.1px;}
#t1g_60{left:909px;bottom:554px;letter-spacing:-0.11px;}
#t1h_60{left:667px;bottom:529px;letter-spacing:-0.09px;}
#t1i_60{left:667px;bottom:513px;letter-spacing:-0.09px;}
#t1j_60{left:733px;bottom:520px;}
#t1k_60{left:293px;bottom:552px;letter-spacing:-0.1px;}
#t1l_60{left:374px;bottom:560px;letter-spacing:-0.1px;}
#t1m_60{left:293px;bottom:509px;letter-spacing:-0.06px;}
#t1n_60{left:293px;bottom:465px;letter-spacing:-0.09px;}
#t1o_60{left:293px;bottom:447px;letter-spacing:-0.11px;}
#t1p_60{left:408px;bottom:454px;letter-spacing:-0.12px;}
#t1q_60{left:293px;bottom:410px;letter-spacing:-0.1px;}
#t1r_60{left:293px;bottom:373px;letter-spacing:-0.1px;}
#t1s_60{left:293px;bottom:355px;letter-spacing:-0.1px;}
#t1t_60{left:381px;bottom:362px;letter-spacing:-0.15px;}
#t1u_60{left:36px;bottom:470px;letter-spacing:-0.1px;}
#t1v_60{left:231px;bottom:478px;}
#t1w_60{left:35px;bottom:313px;letter-spacing:-0.1px;}
#t1x_60{left:35px;bottom:294px;letter-spacing:-0.09px;}
#t1y_60{left:36px;bottom:267px;}
#t1z_60{left:47px;bottom:261px;letter-spacing:0.12px;}
#t20_60{left:521px;bottom:261px;letter-spacing:0.14px;}
#t21_60{left:45px;bottom:247px;letter-spacing:0.11px;word-spacing:-0.05px;}
#t22_60{left:283px;bottom:247px;}
#t23_60{left:36px;bottom:240px;}
#t24_60{left:43px;bottom:234px;letter-spacing:0.12px;}
#t25_60{left:45px;bottom:220px;letter-spacing:0.12px;}
#t26_60{left:45px;bottom:206px;letter-spacing:0.11px;}
#t27_60{left:45px;bottom:192px;letter-spacing:0.12px;}
#t28_60{left:251px;bottom:192px;letter-spacing:0.05px;word-spacing:0.11px;}
#t29_60{left:336px;bottom:192px;}
#t2a_60{left:36px;bottom:185px;}
#t2b_60{left:47px;bottom:179px;letter-spacing:0.12px;}
#t2c_60{left:45px;bottom:165px;letter-spacing:0.1px;word-spacing:0.02px;}
#t2d_60{left:36px;bottom:157px;}
#t2e_60{left:43px;bottom:151px;letter-spacing:-0.03px;}
#t2f_60{left:253px;bottom:151px;}
#t2g_60{left:36px;bottom:143px;}
#t2h_60{left:50px;bottom:137px;letter-spacing:-0.03px;}
#t2i_60{left:81px;bottom:137px;letter-spacing:-0.03px;word-spacing:-0.07px;}
#t2j_60{left:360px;bottom:137px;letter-spacing:-0.04px;}
#t2k_60{left:45px;bottom:124px;letter-spacing:-0.01px;}
#t2l_60{left:93px;bottom:124px;}
#t2m_60{left:36px;bottom:116px;}
#t2n_60{left:47px;bottom:110px;letter-spacing:0.12px;word-spacing:-0.03px;}
#t2o_60{left:557px;bottom:110px;}
#t2p_60{left:675px;bottom:244px;}
#t2q_60{left:685px;bottom:238px;letter-spacing:0.1px;word-spacing:0.02px;}
#t2r_60{left:683px;bottom:221px;letter-spacing:0.12px;}
#t2s_60{left:675px;bottom:214px;}
#t2t_60{left:685px;bottom:208px;letter-spacing:-0.04px;}
#t2u_60{left:683px;bottom:194px;letter-spacing:-0.04px;}
#t2v_60{left:683px;bottom:180px;letter-spacing:-0.03px;}
#t2w_60{left:675px;bottom:172px;}
#t2x_60{left:685px;bottom:166px;letter-spacing:-0.03px;}
#t2y_60{left:683px;bottom:153px;letter-spacing:-0.04px;word-spacing:-0.03px;}
#t2z_60{left:683px;bottom:139px;letter-spacing:-0.04px;}
#t30_60{left:683px;bottom:125px;letter-spacing:-0.04px;}
#t31_60{left:683px;bottom:111px;letter-spacing:-0.03px;}
#t32_60{left:992px;bottom:111px;letter-spacing:-0.02px;}
#t33_60{left:1064px;bottom:111px;letter-spacing:-0.07px;}
#t34_60{left:336px;bottom:303px;letter-spacing:-0.35px;}
#t35_60{left:667px;bottom:629px;letter-spacing:-0.1px;}
#t36_60{left:667px;bottom:610px;letter-spacing:-0.09px;}
#t37_60{left:670px;bottom:345px;letter-spacing:-0.1px;}
#t38_60{left:670px;bottom:326px;letter-spacing:-0.09px;}
#t39_60{left:479px;bottom:466px;letter-spacing:-0.14px;}
#t3a_60{left:666px;bottom:426px;letter-spacing:-0.1px;}
#t3b_60{left:908px;bottom:433px;letter-spacing:-0.15px;}
#t3c_60{left:666px;bottom:408px;letter-spacing:-0.09px;}
#t3d_60{left:904px;bottom:415px;}
#t3e_60{left:666px;bottom:389px;letter-spacing:-0.1px;}
#t3f_60{left:666px;bottom:371px;letter-spacing:-0.13px;}
#t3g_60{left:689px;bottom:378px;}
#t3h_60{left:706px;bottom:371px;letter-spacing:-0.1px;}
#t3i_60{left:666px;bottom:489px;letter-spacing:-0.1px;}
#t3j_60{left:908px;bottom:496px;letter-spacing:-0.15px;}
#t3k_60{left:666px;bottom:470px;letter-spacing:-0.1px;}
#t3l_60{left:666px;bottom:452px;letter-spacing:-0.13px;}
#t3m_60{left:688px;bottom:459px;}
#t3n_60{left:704px;bottom:452px;letter-spacing:-0.1px;}
#t3o_60{left:466px;bottom:416px;letter-spacing:-0.13px;}
#t3p_60{left:529px;bottom:416px;letter-spacing:-0.1px;}
#t3q_60{left:609px;bottom:424px;letter-spacing:-0.1px;}
#t3r_60{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_60{font-size:9px;font-family:ArialMT_5tg;color:#000;}
.s1_60{font-size:5px;font-family:ArialMT_5tg;color:#000;}
.s2_60{font-size:12px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_60{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_60{font-size:17px;font-family:ArialMT_5tg;color:#0065A4;}
.s5_60{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s6_60{font-size:17px;font-family:Arial-BoldMT_5te;color:#0065A4;}
.s7_60{font-size:14px;font-family:Arial-BoldMT_5te;color:#000;}
.s8_60{font-size:14px;font-family:Arial-BoldMT_jz;color:#000;}
.s9_60{font-size:17px;font-family:Arial-BoldMT_jz;color:#000;}
.sa_60{font-size:12px;font-family:ArialMT_5tg;color:#000;}
.sb_60{font-size:15px;font-family:ArialMT_5tg;color:#000;}
.sc_60{font-size:15px;font-family:ArialMT_5tg;color:#0065A4;}
.sd_60{font-size:15px;font-family:ArialMT_k0;color:#000;}
.se_60{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts60" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_jz;
	src: url("fonts/Arial-BoldMT_jz.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

@font-face {
	font-family: ArialMT_k0;
	src: url("fonts/ArialMT_k0.woff") format("woff");
}

</style>
<div id="pg60Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg60" style="-webkit-user-select: none;"><object width="1210" height="935" data="60/60.svg" type="image/svg+xml" id="pdf60" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_60" class="t s0_60">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_60" class="t s1_60">® </span>
<span id="t3_60" class="t s0_60">(NCCN </span>
<span id="t4_60" class="t s1_60">® </span>
<span id="t5_60" class="t s0_60">), All rights reserved. NCCN Guidelines </span>
<span id="t6_60" class="t s1_60">® </span>
<span id="t7_60" class="t s0_60">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_60" class="t s2_60">Note: All recommendations are category 2A unless otherwise indicated. </span>
<span id="t9_60" class="t s2_60">Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. </span>
<span id="ta_60" class="t s3_60">NCCN Guidelines Version 4.2024 </span>
<span id="tb_60" class="t s3_60">Ethmoid Sinus Tumors </span>
<span id="tc_60" class="t s4_60">NCCN Guidelines Index </span>
<span id="td_60" class="t s4_60">Table of Contents </span>
<span id="te_60" class="t s4_60">Discussion </span>
<span id="tf_60" class="t s5_60">ETHM-2 </span>
<span id="tg_60" class="t s5_60">CLINICAL </span>
<span id="th_60" class="t s5_60">PRESENTATION </span>
<span id="ti_60" class="t s5_60">PRIMARY TREATMENT </span><span id="tj_60" class="t s5_60">ADJUVANT TREATMENT </span><span id="tk_60" class="t s5_60">FOLLOW-UP </span>
<span id="tl_60" class="t s5_60">Follow-up </span>
<span id="tm_60" class="t s6_60">(FOLL-A, 1 </span>
<span id="tn_60" class="t s6_60">of 2) </span>
<span id="to_60" class="t s5_60">Recurrent </span>
<span id="tp_60" class="t s5_60">or </span>
<span id="tq_60" class="t s5_60">persistent </span>
<span id="tr_60" class="t s5_60">disease </span>
<span id="ts_60" class="t s6_60">(ADV-3) </span>
<span id="tt_60" class="t s5_60">RT </span>
<span id="tu_60" class="t s7_60">m </span>
<span id="tv_60" class="t s5_60">or </span>
<span id="tw_60" class="t s5_60">Observe </span>
<span id="tx_60" class="t s7_60">p </span>
<span id="ty_60" class="t s5_60">for T1 only (category 2B) </span>
<span id="tz_60" class="t s5_60">or </span>
<span id="t10_60" class="t s5_60">Consider systemic therapy/RT </span>
<span id="t11_60" class="t s7_60">m,n </span>
<span id="t12_60" class="t s5_60">(category 2B) if adverse pathologic </span>
<span id="t13_60" class="t s5_60">features </span>
<span id="t14_60" class="t s8_60">q </span>
<span id="t15_60" class="t s5_60">Resection </span>
<span id="t16_60" class="t s7_60">h,k,l </span>
<span id="t17_60" class="t s5_60">(preferred) </span>
<span id="t18_60" class="t s5_60">or </span>
<span id="t19_60" class="t s9_60" data-mappings='[[2,"fi"]]'>Deﬁnitive RT </span>
<span id="t1a_60" class="t s7_60">m </span>
<span id="t1b_60" class="t s5_60">Newly diagnosed T1,T2 </span>
<span id="t1c_60" class="t s5_60">RT </span>
<span id="t1d_60" class="t s7_60">m </span>
<span id="t1e_60" class="t s5_60">or </span>
<span id="t1f_60" class="t s5_60">Consider systemic therapy/RT </span>
<span id="t1g_60" class="t s7_60">m,n </span>
<span id="t1h_60" class="t s5_60">(category 2B) if adverse pathologic </span>
<span id="t1i_60" class="t s5_60">features </span>
<span id="t1j_60" class="t s8_60">q </span>
<span id="t1k_60" class="t s5_60">Resection </span>
<span id="t1l_60" class="t s7_60">h,k,l </span>
<span id="t1m_60" class="t s5_60">or </span>
<span id="t1n_60" class="t s5_60">Induction </span>
<span id="t1o_60" class="t s5_60">chemotherapy </span>
<span id="t1p_60" class="t s7_60">n,o </span>
<span id="t1q_60" class="t s5_60">or </span>
<span id="t1r_60" class="t s5_60">Concurrent systemic </span>
<span id="t1s_60" class="t s5_60">therapy/RT </span>
<span id="t1t_60" class="t s7_60">m,n </span>
<span id="t1u_60" class="t s5_60">Newly diagnosed T3,T4a </span>
<span id="t1v_60" class="t s7_60">j </span>
<span id="t1w_60" class="t s5_60">Newly diagnosed T4b </span>
<span id="t1x_60" class="t s5_60">or patient declines surgery </span>
<span id="t1y_60" class="t sa_60">h </span>
<span id="t1z_60" class="t sb_60">See the salivary gland algorithm for management after resection. See </span><span id="t20_60" class="t sc_60">NCCN Guidelines </span>
<span id="t21_60" class="t sc_60">for Salivary Gland Tumors (SALI-1)</span><span id="t22_60" class="t sb_60">. </span>
<span id="t23_60" class="t sa_60">j </span>
<span id="t24_60" class="t sb_60">For SNUC with neuroendocrine features, small cell, high-grade olfactory </span>
<span id="t25_60" class="t sb_60">esthesioneuroblastoma, or SNEC histologies, systemic therapy should be a part of the </span>
<span id="t26_60" class="t sb_60">overall treatment. Consider a clinical trial and referral to a major medical center that </span>
<span id="t27_60" class="t sd_60">specializes in these diseases. </span><span id="t28_60" class="t sc_60">See SYST-A</span><span id="t29_60" class="t sb_60">. </span>
<span id="t2a_60" class="t sa_60">k </span>
<span id="t2b_60" class="t sd_60">N+ neck disease is uncommon in ethmoid cancers, but, if present, requires neck </span>
<span id="t2c_60" class="t sb_60">dissection and appropriate risk-based adjuvant therapy. </span>
<span id="t2d_60" class="t sa_60">l </span>
<span id="t2e_60" class="t sc_60">Principles of Surgery (SURG-A)</span><span id="t2f_60" class="t sb_60">. </span>
<span id="t2g_60" class="t sa_60">m </span>
<span id="t2h_60" class="t sb_60">See </span><span id="t2i_60" class="t sc_60">Principles of Radiation Therapy (ETHM-A)</span><span id="t2j_60" class="t sb_60">. For minor salivary gland tumors, see </span>
<span id="t2k_60" class="t sc_60">SALI-A</span><span id="t2l_60" class="t sb_60">. </span>
<span id="t2m_60" class="t sa_60">n </span>
<span id="t2n_60" class="t sc_60">Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)</span><span id="t2o_60" class="t sb_60">. </span>
<span id="t2p_60" class="t sa_60">o </span>
<span id="t2q_60" class="t sb_60">Nonsurgical RT-based treatment is an option in selected patients with </span>
<span id="t2r_60" class="t sb_60">disease that has a major response to induction therapy short of a CR. </span>
<span id="t2s_60" class="t sa_60">p </span>
<span id="t2t_60" class="t sb_60">Pathologic features: negative margins, favorable histology (including low </span>
<span id="t2u_60" class="t sb_60">grade), not located along the cribriform plate or medial wall of the orbit, no </span>
<span id="t2v_60" class="t sb_60">perineural invasion, and lymphovascular space invasion. </span>
<span id="t2w_60" class="t sa_60">q </span>
<span id="t2x_60" class="t sb_60">Adverse pathologic features: positive margins, close margins (tumors </span>
<span id="t2y_60" class="t sb_60">adjacent to the cribriform plate and/or medial wall of the orbit), unfavorable </span>
<span id="t2z_60" class="t sb_60">histology (ie, high grade, adenoid cystic), intracranial and/or intraorbital </span>
<span id="t30_60" class="t sb_60">extension, cribriform plate location, medial wall of orbit location, perineural </span>
<span id="t31_60" class="t sb_60">invasion, and lymphovascular space invasion (</span><span id="t32_60" class="t sc_60">Discussion</span><span id="t33_60" class="t sb_60">). </span>
<span id="t34_60" class="t s6_60">ADV-1 </span>
<span id="t35_60" class="t s6_60">Post Systemic Therapy/RT or RT </span>
<span id="t36_60" class="t s6_60">Neck Evaluation (FOLL-A, 2 of 2) </span>
<span id="t37_60" class="t s6_60">Post Systemic Therapy/RT or RT </span>
<span id="t38_60" class="t s6_60">Neck Evaluation (FOLL-A, 2 of 2) </span>
<span id="t39_60" class="t s5_60">CR </span>
<span id="t3a_60" class="t s5_60">Consider systemic therapy/RT </span>
<span id="t3b_60" class="t s7_60">m,n </span>
<span id="t3c_60" class="t s5_60">if adverse pathologic features </span>
<span id="t3d_60" class="t s8_60">q </span>
<span id="t3e_60" class="t s5_60">or </span>
<span id="t3f_60" class="t s5_60">RT </span>
<span id="t3g_60" class="t s7_60">m </span>
<span id="t3h_60" class="t s5_60">(category 2B) </span>
<span id="t3i_60" class="t s5_60">Consider systemic therapy/RT </span>
<span id="t3j_60" class="t s7_60">m,n </span>
<span id="t3k_60" class="t s5_60">or </span>
<span id="t3l_60" class="t s5_60">RT </span>
<span id="t3m_60" class="t s7_60">m </span>
<span id="t3n_60" class="t s5_60">(category 2B) </span>
<span id="t3o_60" class="t s5_60">&lt;CR </span><span id="t3p_60" class="t s5_60">Resection </span>
<span id="t3q_60" class="t s7_60">h,l </span>
<span id="t3r_60" class="t se_60">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
